Sinotherapeutics Inc. wins approval for Metformin Hydrochloride Sustained Release Tablets (Geshurui) both in USA and China, the first generic drug that was registered with both FDA and CFDA.

Zhejiang Hisun Sinotherapeutics Pharmaceutical Co., Ltd recently announced that Metformin Hydrochloride Sustained Release Tablets (0.5g) has been approved by NMPA for launch. (NMPN H20193023)

Metformin Hydrochloride Sustained Release Tablets, developed by Sinotherapeutics Inc. and manufactured by the authorized manufacturer, Shanghai Sinotherapeutics Haimen Pharmaceutical Co., Ltd, has achieved FDA approval in March 2018 and became the first generic drug that was registered with both FDA and CFDA, which could be treated as the quality consistency evaluation approval.

Chongqing Enchuang Medical Management Co., Ltd has obtained the exclusive right to operate the market launch,  promotion and sales all over the world.  As a first-line therapy and long-term therapy treating type II diabetes, Hydrochloride Sustained Release Tablets feature significant clinical effects.  The launch of Geruishu® in China will benefit a large number of diabetics with drugs of quite lower prices but exactly the same effects along with the same quality, the same safety assurance comparing with the imported originator equivalents they might be using.    

Sinotherapeutics Inc. will continue to introduce high-end generic drugs to domestic market with the global standard R&D technology and manufacturing capability to benefit Chinese patients.